Literature DB >> 11471984

Wild-type p53-function is not required for hyperthermia-enhanced cytotoxicity of cisplatin.

C van Bree1, N A Franken, F A Snel, J Haveman, P J Bakker.   

Abstract

The objective was to test the hypothesis that wild-type p53-function is required for the enhancement of the cytotoxicity of cis-diammine-dichloroplatinum(II) (cDDP) cytotoxicity by hyperthermia (HT). Human colorectal carcinoma cells (RKO) with wild-type p53-function and transfectants with HPV16-E6 or with a dominant negative mutant p53 were used. Cells were treated with HT (60 min at 41 degrees C, 43 degrees C, 45 degrees C: HT41, HT43, HT45). with various doses of cDDP alone or with a combined treatment, simultaneously applied. Survival was determined by clonogenic assays. Levels and localization of p53 were analysed with immunocytochemistry and Western blotting. The extent of HT41-enhanced cytotoxicity of cDDP was similar in all cell lines studied. Immunocytochemistry of wild-type p53 cells showed that p53 is transferred to the nucleus within 5 h after HT43, whilst after HT41 no significant effects were observed. Cell fractionation experiments of wild-type p53 cells showed that, immediately after HT43/HT45, nuclear p53-levels increased as compared to controls, but could not be extracted from the matrix. The extractability was restored 3-5 h after treatment. No significant differences in p53-levels were observed after HT41. These results indicate that, although HT43/HT45 might shortly inactivate p53-function, probably by protein aggregation to the nuclear matrix, the HT-enhanced cDDP-cytotoxicity does not depend on p53-function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11471984     DOI: 10.1080/02656730110053137

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  4 in total

Review 1.  Thermal potentiation of chemotherapy by magnetic nanoparticles.

Authors:  Madeline Torres-Lugo; Carlos Rinaldi
Journal:  Nanomedicine (Lond)       Date:  2013-10       Impact factor: 5.307

2.  Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.

Authors:  Arlene L Oei; Caspar M van Leeuwen; Vidhula R Ahire; Hans M Rodermond; Rosemarie Ten Cate; Anneke M Westermann; Lukas J A Stalpers; Johannes Crezee; H Petra Kok; Przemek M Krawczyk; Roland Kanaar; Nicolaas A P Franken
Journal:  Oncotarget       Date:  2017-04-25

3.  Sensitizing thermochemotherapy with a PARP1-inhibitor.

Authors:  Arlene L Oei; Lianne E M Vriend; Caspar M van Leeuwen; Hans M Rodermond; Rosemarie Ten Cate; Anneke M Westermann; Lukas J A Stalpers; Johannes Crezee; Roland Kanaar; H Petra Kok; Przemek M Krawczyk; Nicolaas A P Franken
Journal:  Oncotarget       Date:  2017-03-07

4.  The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines.

Authors:  Roxan F C P A Helderman; Daan R Löke; Jan Verhoeff; Hans M Rodermond; Gregor G W van Bochove; Menno Boon; Sanne van Kesteren; Juan J Garcia Vallejo; H Petra Kok; Pieter J Tanis; Nicolaas A P Franken; Johannes Crezee; Arlene L Oei
Journal:  Cells       Date:  2020-07-25       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.